Search clinical trials for: Intermediate Risk Prostate Cancer

Total 100021 results

Loma Linda University
National Cancer Institute (NCI); World Cancer Research Fund International; Ardmore...

Active, not recruiting

Plant-based Diets and Risk of Cancer in the Adventist Health Study-2 (AHS-2)

Cancer, Breast | Cancer, Prostate | Cancer, Colorectal

United States
David VanderWeele

Terminated

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer (ADDItion)

Castrate Resistant Prostate Cancer

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Sarcoma

United States
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
Washington University School of Medicine
Johns Hopkins University; National Cancer Institute (NCI); Wake Forest University

Active, not recruiting

Prostate Cancer Prospective Cohort

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Sarcoma | Metastatic Melanoma | Thyroid Gland Carcinoma | Metastatic Malignant Neoplasm of Unknown Primary | Spinal Cord Compression | Stage IV Breast Cancer AJCC v6 and v7 | Malignant Digestive System Neoplasm | Metastatic Malignant Neoplasm in the Spine | Metastatic Kidney Carcinoma | Metastatic Head... and other conditions

United States
University of Florida

Completed

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer (PR05)

Prostate Cancer

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Active, not recruiting

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Prostate

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
CHU de Quebec-Universite Laval
Centre de recherche du Centre hospitalier universitaire de Sherbrooke; McGill... and other collaborators

Active, not recruiting

Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE) (BIOCaPPE)

Prostate Cancer | Epidemiology

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
Ankara Etlik City Hospital

Completed

Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

Turkey
Erasmus Medical Center

Completed

MRI in PROstate Cancer Diagnosis With Prior Risk Assessment (MR-PROPER)

Prostate Cancer

Netherlands
Dan Zandberg
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Belfast Health and Social Care Trust

Active, not recruiting

SPORT High-Risk Trial Evaluating SABR in Prostate Cancer (SPORT)

Prostate Cancer

United Kingdom
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
The Methodist Hospital Research Institute

Completed

68 Ga-PSMA for High Risk Prostate Cancer

Prostate Cancer | High Risk

United States
Mayo Clinic

Completed

Screening CEDM in Intermediate and High-Risk Patient Populations

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals; University of Michigan; University of Texas Southwestern...

Completed

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Prostate Cancer

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...
Amgen

Completed

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (EUROPE)

Myelodysplastic Syndromes

France, Germany
NCIC Clinical Trials Group

Terminated

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer (DART)

Prostate Cancer

Canada
Rennes University Hospital

Completed

Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study (ADTCR)

Prostate Cancer | Androgen-deprivation Therapy

France
University of Sydney
Memorial Sloan Kettering Cancer Center; Bayer; Canadian Cancer Trials Group; Australian... and other collaborators

Active, not recruiting

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

Prostate Cancer

United States, Canada, Australia, United Kingdom, New Zealand, Ireland
Bezmialem Vakif University

Completed

Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia

Hematuria | Retention, Urinary | Operative Bleeding | Blood Transfusion Complication

Turkey
Johnson & Johnson International (Singapore) Pte...

Completed

A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy (ACE)

High Risk Localized Prostate Cancer

Japan, Korea, Republic of, Taiwan
Spanish Breast Cancer Research Group
Eli Lilly and Company

Active, not recruiting

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (CARABELA)

Early Breast Cancer

Spain
Alliance Foundation Trials, LLC.
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Mayo Clinic; University of Chicago; University of Pittsburgh; University of Southern... and other collaborators

Active, not recruiting

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Germ Cell Tumors

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Prostate Carcinoma

United States
University of Sydney
Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer...

Active, not recruiting

Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer (BCG+MM)

Bladder Cancer

Australia, United Kingdom
Celgene

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Myelodysplastic Syndromes

Japan
Bristol-Myers Squibb

Completed

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (DIM Vidaza)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

China
Stanford University

Temporarily not available

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Prostate Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Prostate Cancer

United States, Canada
Cancer Trials Ireland
Janssen, LP

Completed

Neo-adjuvant Abiraterone Prostate Study

High Risk Localised Prostate Carcinoma

Ireland
Cancer Trials Ireland

Active, not recruiting

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

Prostate Cancer

Ireland
Rete Oncologica Piemonte, Valle d'Aosta
Azienda Ospedaliera Città della Salute e della Scienza di Torino; Compagnia...

Completed

Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START (START)

Prostatic Neoplasm

Italy
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
University College, London
King's College London; Imperial College London; Medical Research Council; Cancer...

Active, not recruiting

ReIMAGINE Prostate Cancer Risk

Prostate Cancer

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1

United States
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Prostate Neoplasms

Canada, France, Poland, Ukraine, United Kingdom, China, Belgium, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, Germany, Malaysia, Romania, South Africa, Turkey, Korea, Republic of, Japan, Australia, Netherlands, Sweden, New Zealand and more
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaborators

Active, not recruiting

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Prostate Cancer

United States, Canada
Danish Gynecological Cancer Group
European Organisation for Research and Treatment of Cancer - EORTC; Belgian... and other collaborators

Active, not recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Endometrial Cancer

Denmark
H. Lee Moffitt Cancer Center and Research Institute

Completed

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

Prostate Cancer

United States
UNICANCER
Sanofi; AstraZeneca

Completed

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Prostate Cancer

France
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation

Search clinical trials for: Intermediate Risk Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations